

Report of a WHO expert consultation on dosing to enable implementation of treatment recommendations in the WHO consolidated guidelines on the management of TB in children and adolescents



Report of a WHO expert consultation on dosing to enable implementation of treatment recommendations in the WHO consolidated guidelines on the management of TB in children and adolescents Report of a WHO expert consultation on dosing to enable implementation of treatment recommendations in the WHO consolidated guidelines on the management of TB in children and adolescents

ISBN 978-92-4-005519-3 (electronic version) ISBN 978-92-4-005520-9 (print version)

© World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

Suggested citation. Report of a WHO expert consultation on dosing to enable implementation of treatment recommendations in the WHO consolidated guidelines on the management of TB in children and adolescents. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/copyright.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

Acknowledgements iv					
Abbreviations and acronymsv					
Exec	Executive summaryvi				
1.	Introduction	1			
	1.1 Background and rationale	1			
	1.2 Objectives of the expert consultation	1			
	1.3 Meeting participants	2			
	1.4 Report structure	2			
2.	Dosing of bedaquiline in children	3			
	2.1 Background	3			
	2.2 Key PK features of bedaquiline and evidence reviewed	4			
	2.3 Methodology of data review	6			
	2.4 Dosing options for bedaquiline	8			
	2.5 Research priorities	. 11			
3. D	osing of delamanid in children	. 13			
	3.1 Background	. 13			
	3.2 Key PK features of delamanid and evidence reviewed	. 14			
	3.3 Methodology of data review	. 16			
	3.4 Dosing options for delamanid	. 17			
	3.5 Research priorities	. 20			
4. D	osing of first-line anti-TB drugs in children and adolescents	22			
	4.1 Optimization of dosage for the first-line medicines (rifampicin, isoniazid, pyrazinamide and ethambutol) in the treatment of drug-susceptible TB in children: review of clinical outcomes and pharmacokinetics	22			
	4.2 Update on the use of higher doses of rifampicin in the Opti-Rif study	22			
	4.3 Discussion	. 22			
5. D	osing of the 6-month intensive treatment regimen for TBM	. 24			
	5.1 Background	24			
	5.2 Summary of the presentations	. 24			
	5.3 Dosing of the 6-month intensive TBM regimen	. 27			
	5.4 Considerations on dosing of the TBM regimen in children	. 30			
	5.5 Research priorities for the treatment of paediatric TBM	. 30			
6. C	onclusions and next steps	.31			
Refe	erences	. 32			
Annex 1. List of participants to the expert consultation on dosing considerations for bedaquiline, delamanid and the short intensive regimen to treat tuberculosis meningitis					
Annex 2. Agenda of the expert consultation on dosing considerations for bedaquiline, delamanid and the short intensive regimen to treat tuberculosis meningitis					
Ann	ex 3. Selected definitions of terms used in paediatric population pharmacokinetic modelling, with				
important implications for dosing specific to this report					

Acknowledgements

The World Health Organization (WHO) Global Tuberculosis Programme gratefully acknowledges the contributions of Elin Svensson (Radboud University, The Netherlands), Kelly Dooley (Johns Hopkins University, United States of America), and Paolo Denti and Roeland Wasmann (University of Cape Town, South Africa) in undertaking the evidence reviews ahead of the consultation.

WHO also acknowledges the meeting participants for their contributions to the discussions summarized in this report (see annex 1 for a list of participants).

A first draft of this report was developed by Louvina van der Laan (Stellenbosch University, South Africa) with support from Anneke Hesseling (Stellenbosch University, South Africa) and further refined by Tiziana Masini, Sabine Verkuijl, Annemieke Brands and Kerri Viney, under the supervision of Farai Mavhunga, Unit Head, Vulnerable Populations, Communities and Comorbidities Unit of the WHO Global Tuberculosis Programme.

Abbreviations and acronyms

AIDS	acquired immunodeficiency syndrome		
ART	antiretroviral therapy		
AUC	area under the concentration-time curve		
BID	twice daily		
C _{max}	maximum plasma concentration		
CNS	central nervous system		
CSF	cerebrospinal fluid		
СҮР	cytochrome P450		
DM-6705	delamanid main metabolite (M1)		
DS-TB	drug-susceptible tuberculosis		
DT	dispersible tablet		
ECG	electrocardiogram		
EMA	European Medicines Agency		
Eto	ethionamide		
FDC	fixed-dose combination		
GDF	Global Drug Facility		
GDG	Guideline Development Group		
н	isoniazid		
HIV	human immunodeficiency virus		
IQR	interquartile range		
M1	delamanid main metabolite (DM-6705)		
M2	bedaquiline N-desmethyl metabolite		
MDR/RR-TB	multidrug- or rifampicin-resistant tuberculosis		
MDR-TB	multidrug-resistant tuberculosis		
MIC	minimal inhibitory concentration		
PD	pharmacodynamic		
РК	pharmacokinetic		
QD	once daily		
R	rifampicin		
RR-TB	rifampicin-resistant tuberculosis		
ТВ	tuberculosis		
ТВМ	tuberculous meningitis		
TIW	thrice weekly (Monday/Wednesday/Friday)		
US FDA	United States Food and Drug Administration		
z	pyrazinamide		

Executive summary

The World Health Organization's (WHO's) Global Tuberculosis (TB) Programme convened a Guideline Development Group (GDG) meeting in May–June 2021 to review questions on the management of TB in children and adolescents. Based on the evidence reviewed, WHO conditionally recommended the use of bedaquiline in children with multidrug- or rifampicin-resistant TB (MDR/RR-TB) aged below 6 years, as part of shorter and longer regimens, and the use of delamanid in children with MDR/RR-TB aged below 3 years, as part of longer regimens. In addition, a 6-month intensive regimen (6HRZEto) was conditionally recommended for use in children and adolescents with bacteriologically confirmed or clinically diagnosed tuberculous meningitis (TBM) (without suspicion or evidence of MDR/RR-TB), as an alternative to the currently recommended 12-month regimen (2HRZE/10HR).¹

As a follow-up to the GDG meeting, an online expert consultation was convened by the WHO Global Tuberculosis Programme on 26–27 October 2021, to address dosing of bedaquiline, delamanid and the short intensive TBM regimen. At this meeting, decisions on the dosing of bedaquiline and delamanid in younger children were informed by finding a balance between efficacy (i.e. ensuring that high enough exposures are reached that approximate adult exposures, which have been found to be effective in treating MDR/RR-TB), safety (i.e. avoiding exposures that are too high, which may result in unacceptable toxicity) and implementation considerations (e.g. the availability of child-friendly formulations, acceptability and accessibility).

The meeting participants had expertise in clinical pharmacology, pharmacokinetics and pharmacodynamics, the clinical management of paediatric TB, research, policy, community engagement and programmatic implementation (see annex 1 for the list of participants annex 2 and for the meeting agenda). This meeting report summarizes the discussions and advice provided to WHO with respect to the dosing of bedaquiline, delamanid and the short intensive TBM regimen.

WHO has used the advice provided by meeting participants to update the dosing table for bedaquiline and delamanid used in MDR/RR-TB regimens in children and adolescents who weigh less than 46 kg, as part of a comprehensive update of the dosing table for second-line TB drugs. The advice also informed the development of a dosing table for the shorter 6-month intensive TBM regimen that has now been included in the 2022 WHO operational handbook on the management of TB in children and adolescents.²

Bedaquiline

Bedaquiline forms a core component of current MDR/RR-TB treatment, both as a Group A drug for use in longer regimens and as a component of the shorter regimen. Although available pharmacokinetic (PK) and safety data in children are limited, interim dosing guidance can be based on an analysis of existing data using population PK modelling and simulation tools. Dosing of bedaquiline in children is known to be affected by body weight and age.^{3,4} The PK parameters of bedaquiline in adults have been well described and are informed by a larger body of evidence.⁵ By accounting for age, body weight and other known covariates, an adult population PK model was used to simulate dose-exposure scenarios for a virtual representative paediatric population. In addition, individual paediatric data from various studies – the IMPAACT P1108 study, the Janssen TMC207-C211 trial and the MDR-PK2 observational study – were used to evaluate a virtual population PK methods and current paediatric

¹ WHO consolidated guidelines on tuberculosis Module 5: Management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022 (<u>https://apps.who.int/iris/rest/bitstreams/1414329/retrieve</u>).

² WHO operational handbook on tuberculosis Module 5: Management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022 (<u>https://apps.who.int/iris/rest/bitstreams/1414333/retrieve</u>).

³ Holford N, Heo Y-A, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102(9):2941–52 (<u>https://pubmed.ncbi.nlm.nih.gov/23650116/</u>).

⁴ Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25–36 (<u>https://pubmed.ncbi.nlm.nih.gov/19252334/</u>).

⁵ Svensson EM, Dosne AG, Karlsson MO. Population pharmacokinetics of bedaquiline and metabolite M2 in patients with drug-resistant tuberculosis: the effect of time-varying weight and albumin. CPT Pharmacometrics Syst Pharmacol. 2016;5(12):682–91 (https://pubmed.ncbi.nlm.nih.gov/27863179/).

bedaquiline PK data, different dosing options were formulated and evaluated. Participants considered a combined age- and weight-based dosing approach for the use of bedaquiline in children aged below 6 years to be the most suitable option. The use of the 20 mg dispersible tablet (DT) formulation of bedaquiline is preferred for dosing young children; however, when that formulation is not available, or the pill burden is thought to be too high, the 100 mg adult formulation can be used (whole or after crushing and dispersing in water).¹ This interim dosing guidance will be reviewed by WHO in the future as new data become available.

The final dosing advice is summarized in table ES1.

Table ES1. Final dosing advice provided by the participants of the expert consultation for the use of bedaquiline in children who weigh less than 46 kg with MDR/RR-TB (with age- and weight-based dosing in children with MDR/RR-TB weighing <16 kg)

×10 Kg/		
Weight range ^a	Age category	Dosing of bedaquiline ^b
3 to <5 kg	0 to <3 months	30 mg QD/10 mg TIW
	≥3 months	60 mg QD/20 mg TIW
	0 to <3 months	30 mg QD/10 mg TIW
5 LO <7 Kg	≥3 months	60 mg QD/20 mg TIW
	0 to <3 months	30 mg QD/10 mg TIW
7 to <10 kg	3 to <6 months	60 mg QD/20 mg TIW
	≥6 months	80 mg QD/40 mg TIW
10 to <16 kg	3 to <6 months	60 mg QD/20 mg TIW
10 to <10 kg	≥6 months	120 mg QD/60 mg TIW
16 to <24 kg	-	200 mg OD (100 mg TIM)
24 to <30 kg	-	200 Hig QD/100 Hig HW
30 to <35 kg ^c	-	
35 to <50 kg	_	400 mg QD/200 mg TIW
≥50 kg	_	

DR-TB: drug-resistant TB; MDR/RR-TB: multidrug- or rifampicin-resistant TB; QD: once a day; TB: tuberculosis; TIW: thrice weekly (Monday/Wednesday/Friday).

^a For dosing of premature and low birth weight infants weighing <3 kg, advice should be sought from a paediatric DR-TB expert.

^b Dosing is provided for the intensive phase (2 weeks) followed by dosing for the continuation phase (22 weeks).

^c The cut-off for this weight band was adjusted in the final dosing table published in the 2022 operational handbook,² to align with the first weight band of the dosing table for patients aged 15 years and older (as in the 2020 WHO operational handbook on tuberculosis Module 4: Treatment – drug-resistant tuberculosis treatment)

Delamanid

Delamanid is a Group C medication that is used in longer regimens to treat MDR/RR-TB. The participants considered different dosing options for delamanid in children aged below 3 years, through review of the

预览已结束,完整报告链接和二维码如下:



https://www.yunbaogao.cn/report/index/report?reportId=5 31615